Last mentioned: Mar 9, 2026
Evolv Technologies and Skye Bioscience are set to report Q4 2025 results, highlighting two critical growth vectors in the healthcare ecosystem: AI-driven physical security and metabolic clinical innovation. While Evolv faces a pivotal moment in hospital infrastructure adoption, Skye’s update will be scrutinized for progress in the competitive obesity therapeutics market.
This page surfaces every story mentioning Evolv Technologies across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Evolv Technologies was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |